Cannabinoid Gut Research Includes Enteric Nerves, Epithelial Cells and Immune Targets
A 2010 review described endocannabinoid signaling across several gut cell types and functions. An effect on intestinal movement should not automatically be reported as evidence about inflammation, secretion or visceral sensation.
The system was distributed rather than uniform
The review identified regional and organ-specific actions involving enteric nerves, epithelial cells and immune cells. The presence of a cannabinoid-related target in the gut does not establish the same response in every tissue or gastrointestinal disorder.
The proposed targets extended beyond CB1 and CB2
The synthesis discussed other receptors and signaling systems alongside cannabinoid receptors and enzymes. This broad pharmacology helps explain why a result with one research agent cannot simply be assigned to THC, CBD or a whole-plant preparation.
Much therapeutic potential came from models
Preclinical evidence can identify a pathway worth testing while leaving clinical efficacy unresolved. Changes in motility, ion transport or a laboratory inflammatory measure do not independently establish symptom relief or disease control in patients.
Interpreting the evidence
For a gastrointestinal claim, identify the cell type, organ, intervention and endpoint. This review provides a mechanistic map, not proof that cannabis treats every gut condition. It also does not establish that one symptom change reflects improvement in the underlying disease.
Related reading: interpreting cannabis tolerance claims.
Research reference
Izzo AA; Sharkey KA (2010). Cannabinoids and the gut: new developments and emerging concepts. Pharmacology & therapeutics. doi:10.1016/j.pharmthera.2009.12.005.
This analysis draws on the supplied review abstract.
